Get started
Author

Hassan Rezaei Kalantari

Observed names: H Rezaei Kalantari, H. Kalantari, Hassan Kalantari, Hassan R. Kalantari, Hassan Rezaie Kalantari
Institution: CHR Verviers
ORCID: 0000-0001-5571-6960
Observed ORCID: 0000-0001-5571-6960
OpenAlex ID: A5036070315
Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX
2017 · Jean-François Emile, Catherine Julié, et al. · European Journal of Cancer · 49
NPY Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
2023 · Katleen Janssens, Greetje Vanhoutte, et al. · Clinical Cancer Research · 15
Real life safety and effectiveness of nivolumab in older patients with non-small cell lung cancer: Results from the Belgian compassionate use program
2019 · Sofie Joris, Thierry Pieters, et al. · Journal of Geriatric Oncology · 14
PDF
Management of high-grade neuroendocrine neoplasms: impact of functional imaging
2025 · O Islam, K Sarti, et al. · Endocrine Related Cancer · 7
Digenic Inheritance of Mutations in Homologous Recombination Genes in Cancer Patients
2024 · Maria Valeria Freire, Marie Martin, et al. · Journal of Personalized Medicine · 2
PDF
Fortnightly or fractionated weekly docetaxel–cisplatin–5‐FU as first‐line treatment in advanced gastric and gastroesophageal junction adenocarcinoma: The randomized phase II DoGE study
2021 · Amélie Deleporte, Marc Van den Eynde, et al. · Cancer Medicine · 1
PDF
Phase II study of irinotecan + 5FU/FA for patients with previously treated advanced gastric cancer
2004 · M. Peeters, J. L. Van Laethem, et al. · Journal of Clinical Oncology · 1
Supplementary Data S1 from NPY Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
2025 · Katleen Janssens, Greetje Vanhoutte, et al.
Supplementary Figure S1 from NPY Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
2025 · Katleen Janssens, Greetje Vanhoutte, et al.
PDF
Supplementary Figure S4 from NPY Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
2025 · Katleen Janssens, Greetje Vanhoutte, et al.
PDF
Supplementary Figure S5 from NPY Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
2025 · Katleen Janssens, Greetje Vanhoutte, et al.
PDF
Supplementary Figure S3 from NPY Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
2025 · Katleen Janssens, Greetje Vanhoutte, et al.
PDF
Supplementary Figure S2 from NPY Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
2025 · Katleen Janssens, Greetje Vanhoutte, et al.
PDF
Supplementary Figure S7 from NPY Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
2025 · Katleen Janssens, Greetje Vanhoutte, et al.
Supplementary Materials and Methods S1 from NPY Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
2025 · Katleen Janssens, Greetje Vanhoutte, et al.
Supplementary Tables S1-S10 from NPY Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
2025 · Katleen Janssens, Greetje Vanhoutte, et al.
Supplementary Figure S6 from NPY Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
2025 · Katleen Janssens, Greetje Vanhoutte, et al.
PDF
Supplementary Figure S2 from NPY Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
2024 · Katleen Janssens, Greetje Vanhoutte, et al.
Supplementary Figure S4 from NPY Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
2024 · Katleen Janssens, Greetje Vanhoutte, et al.
PDF
Supplementary Figure S7 from NPY Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
2024 · Katleen Janssens, Greetje Vanhoutte, et al.
Supplementary Figure S7 from NPY Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
2024 · Katleen Janssens, Greetje Vanhoutte, et al.
Supplementary Figure S2 from NPY Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
2024 · Katleen Janssens, Greetje Vanhoutte, et al.
PDF
Supplementary Figure S1 from NPY Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
2024 · Katleen Janssens, Greetje Vanhoutte, et al.
Supplementary Tables S1-S10 from NPY Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
2024 · Katleen Janssens, Greetje Vanhoutte, et al.
Data from NPY Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
2024 · Katleen Janssens, Greetje Vanhoutte, et al.
Works count: 64
Citation count: 89
H-index: 4
I10-index: 3
Year
Topic
Type